Compare · NSPR vs WST
NSPR vs WST
Side-by-side comparison of InspireMD Inc. (NSPR) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSPR and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.35B, about 1103.4x NSPR ($20.3M).
- Over the past year, NSPR is down 61.0% and WST is up 50.1% - WST leads by 111.1 points.
- NSPR has been more active in the news (8 items in the past 4 weeks vs 7 for WST).
- WST has more recent analyst coverage (16 ratings vs 1 for NSPR).
- Company
- InspireMD Inc.
- West Pharmaceutical Services Inc.
- Price
- $1.01+1.00%
- $316.27+1.21%
- Market cap
- $20.3M
- $22.35B
- 1M return
- -15.13%
- +5.39%
- 1Y return
- -61.00%
- +50.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 1
- 16
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NSPR
- InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)
- InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Commercial Officer Gleason Shane Thomas sold $189,594 worth of shares (85,295 units at $2.22), decreasing direct ownership by 7% to 1,053,882 units (SEC Form 4) (for tax liability)
- Director Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)
- CEO and President Slosman Marvin bought $25,200 worth of shares (21,000 units at $1.20), increasing direct ownership by 0.59% to 3,556,658 units (SEC Form 4)
- Amendment: Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)
- Director Stuka Paul bought $88,026 worth of shares (75,626 units at $1.16), increasing direct ownership by 14% to 632,871 units (SEC Form 4)
- Director Ward Scott R. bought $102,638 worth of shares (89,250 units at $1.15), increasing direct ownership by 60% to 237,096 units (SEC Form 4)
- Director Stuka Paul bought $9,034 worth of shares (7,895 units at $1.14), increasing direct ownership by 2% to 531,599 units (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)